|
|
Volumn 303, Issue 5665, 2004, Pages 1796-1799
|
|
Surviving the Blockbuster Syndrome
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOMEDICAL ENGINEERING;
COSTS;
MERGERS AND ACQUISITIONS;
REORGANIZATION;
SYNDROMES;
DRUG PRODUCTS;
ANTIBODY;
ANTIINFECTIVE AGENT;
DRUG;
PROTEIN;
SIMVASTATIN;
PHARMACEUTICAL INDUSTRY;
ARTICLE;
CLINICAL TRIAL;
COST;
DRUG INDUSTRY;
HUMAN;
PRIORITY JOURNAL;
RESEARCH;
TECHNOLOGY;
BIOMEDICAL RESEARCH;
CHEMISTRY, PHARMACEUTICAL;
CLINICAL TRIALS;
COMBINATORIAL CHEMISTRY TECHNIQUES;
DRUG APPROVAL;
DRUG COSTS;
DRUG DESIGN;
DRUG INDUSTRY;
DRUG UTILIZATION;
DRUGS, GENERIC;
ECONOMICS, PHARMACEUTICAL;
PATENTS;
PHARMACEUTICAL PREPARATIONS;
PHARMACOGENETICS;
PRESCRIPTION FEES;
TECHNOLOGY, PHARMACEUTICAL;
|
|
EID: 1642354534
PISSN: 00368075
EISSN: None
Source Type: Journal
DOI: 10.1126/science.303.5665.1796 Document Type: Article |
|
Times cited : (93)
|
|
References (0)
|